We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Millennium Pharmaceuticals has announced Velcade study results for the treatment
of patients with indolent and mantle cell non-Hodgkin's lymphomas, and Waldenstom's
Macroglobulemia at the 9th International Conference of Malignant Lymphoma in
Lugano, Switzerland.
Results from three recent Phase II studies announced today showed that sitagliptin
phosphate (MK-0431), Merck's investigational medicine in a potentially new class
of agents for the treatment for diabetes called DPP-IV (dipeptidyl peptidase
IV) inhibitors significantly improved glycemic control in patients with Type
2 diabetes compared to placebo.
Bristol-Myers Squibb and Merck & Co. have announced results from both a
Phase III active-controlled study and a long-term Phase II dose-ranging study
for the investigational oral medicine muraglitazar (now known under the registered
trade name Pargluva) during a late-breaking presentation of the 65th Annual
Scientific Sessions of the American Diabetes Association.
Arena Pharmaceuticals has received a U.S. patent, titled "Human G Protein-Coupled
Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders,"
that protects certain drug screening methods that utilize the niacin receptor.
NutraCea has been issued a patent from the U.S. Patent and Trademark Office
titled, "Methods for Treating Joint Inflammation, Pain and Loss of Mobility."
GPC Biotech AG has presented preclinical data on its anticancer monoclonal antibody,
1D09C3, at the 9th International Conference on Malignant Lymphoma in Lugano,
Switzerland.
Regeneron Pharmaceuticals has announced positive preliminary results from an
ongoing pilot study of once-weekly dosing of the Interleukin-1 (IL-1) Trap in
patients with CIAS1-associated periodic syndrome (CAPS), a family of autoinflammatory
diseases.
Seattle Genetics has presented data from its SGN-35 development program at the
9th International Conference on Malignant Lymphoma in Lugano, Switzerland.